Summary:
United States Patent 9,265,725 is a patent granted to Amgen Inc. on February 23, 2016. It covers methods related to the treatment of anemia through administration of specific erythropoiesis-stimulating agents (ESAs). The patent claims focus on dosing regimens, formulations, and methods for enhancing efficacy and reducing adverse effects of ESA therapies. Its scope encompasses proteins, pharmaceutical formulations, and treatment protocols for anemia, particularly in chronic kidney disease.
What Are the Core Claims and Scope of Patent 9,265,725?
Primary Claims Overview
The patent’s claims are structured to protect novel formulations, dosing methods, and specific protein variants of erythropoietin or related ESAs. They aim at:
- Specific dosing regimens that optimize patient outcomes while minimizing side effects.
- Pharmaceutical compositions with particular formulations or stability features.
- Use of the claimed proteins in treating anemia, especially in chronic kidney disease patients.
Key Claims Breakdown
| Claim Category |
Description |
Details |
| Dosing Regimens |
Methods of administering ESA proteins to maintain hemoglobin within a specified range. |
Example: Subcutaneous or intravenous administration to keep hemoglobin between 10-12 g/dL, with dosing intervals ranging from weekly to biweekly. The patent emphasizes flexible dosing schedules tailored to patient response. |
| Protein Variants |
Modified erythropoietin proteins with altered glycosylation or amino acid sequences. |
The claims include ESA variants with specific amino acid modifications designed to prolong half-life and improve stability. |
| Pharmaceutical Formulations |
Formulations with stabilizers, buffers, or preservatives that improve storage and delivery. |
Examples include formulations that maintain activity at room temperature, extend shelf life, or reduce immunogenicity. |
| Methods of Treatment |
Protocols involving administering the described proteins in certain dosages and intervals for treating anemia. |
The claims specify methods for administering biweekly or monthly doses effectively, especially in chronic conditions. |
Scope Limitations and Exclusions
- The patent explicitly excludes proteins with sequences or modifications outside the specified claims.
- It does not cover different delivery methods not disclosed in the patent, such as implantable devices or novel routes beyond injections.
- The claims are limited to the formulations, dosages, or protocols disclosed and do not extend to all ESA-related applications.
Patent Landscape and Related Patent Families
Related Patents and Continuations
The patent is part of a broader patent family held by Amgen, including:
- US 9,637,775 (filed in 2015): Focuses on methods for producing modified erythropoietin proteins.
- US 10,083,722 (filed in 2016): Claims related to specific formulations of erythropoietin with enhanced half-life.
- WO 2017/196283: An international application expanding coverage to formulations and dosing protocols.
Patent Family and Market Context
This patent family covers multiple jurisdictions—Europe, Japan, Canada, and others—ensuring broad international protection for Amgen’s ESA-related inventions. Its strategic scope aligns with Amgen’s commercial product, Epogen, and Mircera, particularly in extending patent protection for novel dosing methods.
Competitive Landscape
- Genentech/Roche’s EPOGEN and Aranesp products primarily operate in similar spaces.
- Other players like Pfizer (with Retacrit, a biosimilar) do not hold patents directly blocking Amgen’s formulations but shape the competitive environment.
- Biosimilar entrants are attempting to challenge patent exclusivity when patents expire, especially post-2025.
Legal Status and Patent Term
- The patent was granted on February 23, 2016, with expiration expected around February 2033, assuming maintenance fee payments.
- Potential patent term adjustments or patent extensions could influence the actual effective duration.
- Pending or filed patent applications may complicate patent enforcement.
Implications for R&D and Commercialization
- The claims covering dosing regimens and formulations are crucial for Amgen’s market exclusivity.
- Exploring variants not covered by the patent presents opportunities for biosimilar development.
- Manufacturers must scrutinize the scope to avoid infringing on specific dosing or formulation claims.
Key Takeaways
- Scope: Focuses on specific ESA proteins, dosing schedules, and formulations optimized for anemia treatment, especially in chronic kidney disease.
- Claims: Cover methods, formulations, and protein variants with detailed parameters.
- Landscape: Part of a substantial patent family protecting Amgen’s ESA portfolio, with plots across various jurisdictions.
- Strategic Considerations: Enforcement hinges on claim interpretation; biosimilar entrants may seek design-arounds or challenge patent validity.
FAQs
1. What specific innovations does Patent 9,265,725 protect?
It protects methods of administering ESA proteins with particular dosing schedules and formulations designed to improve efficacy and safety for anemia patients.
2. How broad are the claims concerning ESA proteins?
Claims cover specific amino acid modifications and glycosylation patterns, not all ESA variants. Variants outside the defined claims are potentially unprotected.
3. Does the patent cover biosimilar versions of erythropoietin?
Not directly. The patent protects specific formulations and protocols; biosimilar manufacturers can develop different proteins or dosing methods outside these claims.
4. For how long does this patent provide exclusivity?
Expected expiration around February 2033, unless extended or challenged.
5. How does this patent influence the development of new anemia treatments?
It constrains development of ESA products based on the protected proteins, formulations, and protocols. Developers must consider patent landscapes when designing new therapies.
References
[1] US Patent 9,265,725.
[2] Amgen Press Release, 2016.
[3] Patent family documents and related applications.
[4] Market analysis reports on ESA patents and biosimilars.
